Major Depressive Disorder, Metabolic Disorder, Psychiatric Disorder
Conditions
Keywords
adolescent MDD, treatment-resistant depression, metabolomic
Brief summary
This study contributes new evidence for the identification of adolescent TRD and sheds light on differing pathophysiologies by delineating distinct plasma metabolic profiles between adolescent TRD and FEDN-MDD.
Interventions
DIAGNOSTIC_TEST17-HAMD
Patients were interviewed in a semi-structured manner and assessed using the 17-item Hamilton Depression Scale and the Hamilton Anxiety Scale
Sponsors
First Affiliated Hospital of Chongqing Medical University
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
12 Years to 18 Years
Healthy volunteers
Yes
Inclusion criteria
FEDN-MDD： 1. Age 12-18 years 2. Meet the diagnostic criteria for MDD according to the DSM-5 3. First-episode and drug-naive 4. HAMD-17 score \> 17 TRD: 1. Age 12-18 years 2. Meet the diagnostic criteria for MDD according to the DSM-5 3. HAMD-17 score \> 13 4. Currently or previously taking a standard therapeutic dose of antidepressant for at least 6 weeks, and they had at least one historical failure to an antidepressant (reduction in depressive symptoms \<50%) HC: 1. age 12-18 years 2. HAMD-17 score \< 7 3. HCs without a personal history of a mental illness or family history in a first-degree relative
Exclusion criteria
FEDN-MDD、TRD： 1. the presence or past history of severe medical, neurological or psychiatric disorders (other than MDD in patients) 2. anxiety comorbidity was not considered an exclusion criterion provided that MDD was the main diagnosis and the primary reason for seeking assistance 3. substance abuse, head trauma, or loss of consciousness 4. Chronic physical diseases that significantly affect peripheral metabolism or neurological function 5. Pregnant and lactating women HC: 1. the presence or past history of severe medical, neurological or psychiatric disorders 2. substance abuse, head trauma, or loss of consciousness 3. Chronic physical diseases that significantly affect peripheral metabolism or neurological function 4. Pregnant and lactating women
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 17 items Hamilton Depression Scale | baseline | The Hamilton Depression Scale assesses the level of depressive symptoms in patients |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Hamilton Anxiety Scale | baseline | The Hamilton Anxiety Scale assesses the level of anxiety symptoms in patients |
Countries
China
Outcome results
None listed